Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke

Pharmacogenetics and Genomics

Volumn 18, Issue 6, 2008, Pages 535-543

  Marciante, Kristin D ^a,b   Totah, Rheem A ^b   Heckbert, Susan R ^a,b,c   Smith, Nicholas L ^a,b,d   Lemaitre, Rozenn N ^a,b   Lumley, Thomas ^a,b   Rice, Kenneth M ^a,b   Hindorff, Lucia A ^a,b   Bis, Joshua C ^a,b   Hartman, Brittany ^a   Psaty, Bruce M ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Cytochrome p 450; Epoxyeicosatrienoic acids; Genetics; Myocardial infarction; Stroke

Indexed keywords

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYP2C8 GENE; CYP2C9 GENE; CYP2J2 GENE; FEMALE; GENE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MYOCARDIAL INFARCTION; ODDS RATIO; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; STROKE; VARIATION (GENETICS);

EID: 44449164336     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282fd1287     Document Type: Article

References (36)

1. Spiecker M, Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 2005; 433:413-420.
2. King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L, et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002; 61:840-852.
3. Fleming I, Busse R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 2006; 47:629-633.
4. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996; 271:3460-3468.
5. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285:1276-1279.
6. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001; 276:36059-36062.
7. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 2007; 35:682-688.
8. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007; 17:731-742.
9. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607.
10. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 2005; 33:630-636.
11. Soyama A, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, Sawada J. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 2002; 17:374-377.
12. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6:429-439.
13. Lee SS, Jeong HE, Liu KH, Ryu JY, Moon T, Yoon CN, et al. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics 2005; 15:105-113.
14. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004; 110:2132-2136.
15. Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM, Chen JH. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007; 195:199-206.
16. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics 2007; 17:349-358.
17. Hoffmann MM, Bugert P, Seelhorst U, Wellnitz B, Winkelmann BR, Boehm BO, Marz W. The -50G> T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2007; 53:539-540.
18. Saunders KWDR, Stergachis A. Group Health Cooperative. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: Wiley; 2005. pp. 223-240.
19. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620-625.
20. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287:1680-1689.
21. Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001; 285:906-913.
22. Price TR, Psaty B, O'Leary D, Burke G, Gardin J. Assessment of cerebrovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1993; 3:504-507.
23. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 1995; 5:278-285.
24. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993; 22:1189-1192.
25. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74:106-120.
26. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
27. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-1169.
28. French B, Lumley T, Monks SA, Rice KM, Hindorff LA, Reiner AP, Psaty BM. Simple estimates of haplotype relative risks in case-control data. Genet Epidemiol 2006; 30:485-494.
29. Lettre G, Lange C, Hirschhorn JN. Genetic model testing and statistical power in population-based association studies of quantitative traits. Genet Epidemiol 2007; 31:358-362.
30. Benjamini YHY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57:289-300.
31. Crawford DC, Nickerson DA. Definition and clinical importance of haplotypes. Annu Rev Med 2005; 56:303-320.
32. Funk M, Endler G, Freitag R, Wojta J, Huber K, Mannhalter C, Sunder-Plassmann R. CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. Clin Chem 2004; 50:2395-2398.
33. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, Rane A. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003; 13:715-720.
34. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001; 52:489-499.
35. Benjamini Y, Yekutieli D. Quantitative trait loci analysis using the false discovery rate. Genetics 2005; 171:783-790.
36. Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K, et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 2007; 297:489-498.